The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort
Abstract
PURPOSE: To retrospectively compare the frequency of administration and cumulative dose of gadolinium-based contrast agent in dialysis-dependent patients who did and those who did not develop nephrogenic systemic fibrosis. MATERIALS AND METHODS: The ethics committees granted exempt status for this study and also waived the need for informed consent. A retrospective analysis was performed of all adult patients undergoing dialysis in the west of Scotland between January 1, 2000, and July 1, 2006. Diagnoses of nephrogenic systemic fibrosis, episodes of gadolinium-enhanced magnetic resonance (MR) imaging, and cumulative doses of gadolinium-based contrast agent were recorded. Outcomes were analyzed by means of parametric and nonparametric testing. RESULTS: Fourteen of 1826 patients had a diagnosis of nephrogenic systemic fibrosis. Mortality was similar for affected and nonaffected patients. Thirteen (93%) of 14 patients with nephrogenic systemic fibrosis had undergone gadolinium-enhanced MR imaging compared with 408 (22.5%) of 1812 nonaffected patients (P<.001). Patients with nephrogenic systemic fibrosis received a higher median cumulative dose of gadodiamide (0.39 vs 0.23 mmol per kilogram of body weight, P=.008) and underwent more gadolinium-enhanced MR imaging than their nonaffected gadolinium-exposed counterparts. CONCLUSION: The data support a positive association between gadolinium-based contrast agent administration and development of nephrogenic systemic fibrosis in the established renal failure population; in addition, there is a positive association between cumulative dose of gadodiamide used and dosing events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grobner, T. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfk062 · Cited by 1,859
Marckmann, P., Skov, L., Rossen, K., Dupont, A., Damholt, M. B., Heaf, J. G., & Thomsen, H. S. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060601 · Cited by 1,400
Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation
Sadowski, E. A., Bennett, L. K., Chan, M. R., Wentland, A. L., Garrett, A. L., Garrett, R. W., & Djamali, A. (2007) · Radiology · doi:10.1148/radiol.2431062144 · Cited by 1,018
Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis
Kuo, P. H., Kanal, E., Abu-Alfa, A. K., & Cowper, S. E. (2007) · Radiology · doi:10.1148/radiol.2423061640 · Cited by 630
Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned
Broome, D. R., Girguis, M. S., Baron, P. W., Cottrell, A. C., Kjellin, I., & Kirk, G. A. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.1094 · Cited by 604
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
High, W. A., Ayers, R. A., Chandler, J., Zito, G., & Cowper, S. E. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.047 · Cited by 545
Gadolinium deposition in nephrogenic fibrosing dermopathy
Boyd, A. S., Zic, J. A., & Abraham, J. L. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.048 · Cited by 373
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
Thomsen, H. S. (2006) · European Radiology · doi:10.1007/s00330-006-0495-8 · Cited by 352
Description of 12 Cases of Nephrogenic Fibrosing Dermopathy and Review of the Literature
Mendoza, F. A., Artlett, C. M., Sandorfi, N., Latinis, K., Piera-Velazquez, S., & Jimenez, S. A. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.08.002 · Cited by 262
Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging
Mark, P. B., Johnston, N., Groenning, B. A., Foster, J. E., Blyth, K. G., Martin, T. N., Steedman, T., Dargie, H. J., & Jardine, A. G. (2006) · Kidney International · doi:10.1038/sj.ki.5000249 · Cited by 262
Self-citation
Cited by
Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned
Broome, D. R., Girguis, M. S., Baron, P. W., Cottrell, A. C., Kjellin, I., & Kirk, G. A. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.1094 · Cited by 604
Gadolinium‐based contrast agents: A comprehensive risk assessment
Fraum, T. J., Ludwig, D. R., Bashir, M. R., & Fowler, K. J. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25625 · Cited by 402
Magnetic Particle Imaging (MPI) for NMR and MRI researchers
Saritas, E. U., Goodwill, P. W., Croft, L. R., Konkle, J. J., Lu, K., Zheng, B., & Conolly, S. M. (2013) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2012.11.029 · Cited by 307
Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers
Prince, M. R., Zhang, H., Morris, M., MacGregor, J. L., Grossman, M. E., Silberzweig, J., DeLapaz, R. L., Lee, H. J., Magro, C. M., & Valeri, A. M. (2008) · Radiology · doi:10.1148/radiol.2483071863 · Cited by 290
Broome, D. R. (2008) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.02.011 · Cited by 283
Metadata
- Authors
- Collidge, T. A., Thomson, P. C., Mark, P. B., Traynor, J. P., Jardine, A. G., Morris, S. T. W., Simpson, K., & Roditi, G. H.
- Venue
- Radiology
- Published
- 2007-10
- Volume
- 245
- Issue
- 1
- Pages
- 168-175
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2104233131
- Cited by
- 319
- References
- 17
- FWCI
- 26.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort. https://app.cochat.ai/papers/10.1148/radiol.2451070353
- The paper
- Collidge, T. A., Thomson, P. C., Mark, P. B., Traynor, J. P., Jardine, A. G., Morris, S. T. W., Simpson, K., & Roditi, G. H. (2007). Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort. Radiology. https://doi.org/10.1148/radiol.2451070353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.